Home
      Diagnosis
      Treatment
      Pathology
      Variants
      CIDP info
      GBS
      IVIG
      Diet
      About Us
       E-Book
      Email Web Weaver
      Autoimmune diseases
      News
      Links
 

 

 

 

 

 

 
 
 
 

                                             New research
     

    CIDPUSA HAS BEEN SAYING FOR YEARS ABOUT EARLY TREATMENT,

IVIG USE......... WE HAVE BEEN PROVEN CORRECT BY THIS STUDY.

 
Curr Treat Options Neurol. 2006 Mar;8(2):91-103.  

Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy.

De Sousa EA, Brannagan TH 3rd.

Department of Neurology, Weill Medical College of Cornell University, 635 Madison Avenue, Suite 400, New York, NY 10022, USA.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated acquired polyneuropathy that may lead to disability. CIDP is characterized by an autoimmune attack against peripheral nervous system myelin, by cellular and humoral mechanisms. Early diagnosis and treatment may yield better functional recovery, probably by minimizing secondary axonal loss from a primary demyelinating insult. Intravenous immunoglobulin and plasmapheresis are considered standard-of-care therapy in CIDP, based on randomized, double-blinded, placebo-controlled evidence. Corticosteroids, despite less robust evidence, are also considered standard therapy for CIDP. Other nonstandard therapies may work in refractory patients.
These include azathioprine, cyclophosphamide, cyclosporine A, etanercept, interferon-alpha 2a, mycophenolate mofetil, and tacrolimus. Emerging therapies include interferon-beta 1a, rituximab, and high-dose cyclophosphamide without stem-cell rescue. Because most patients will require prolonged therapy, long-term side effects are important considerations.

PMID: 16464406 [PubMed]
Resources National Institutes of Health (NIH) Resources